Company: RPTX
Filing Date: 2025-11-14
Form Type: DEFA14A
Source: 0001193125-25-283320
Chunk: 4

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-14
Form: DEFA14A
Chunk 4
---
 payment per Common Share that will be determined based upon Repare’s cash balance at closing of the Transaction (the “Closing”) after deducting certain transaction costs and the aggregate amount of outstanding liabilities (the “Closing Net Cash Amount”). Based on Repare’s current estimates of the Closing Net Cash Amount and the expected timing for Closing, it is currently estimated that each Repare shareholder will receive a cash payment of US$1.82 per Common Share at Closing. In addition, each Repare shareholder will also receive one non-transferable contingent value right (each, a “CVR”) for each Common Share that entitles the holder to receive certain cash payments, including:

| i) | 100% of certain additional receivables that may be received by Repare within ninety (90) days following 
 the Closing (net of certain permitted deductions incurred in connection therewith);                     |

| ii) | A percentage of the net proceeds received from Repare’s existing partnerships with Bristol-Myers Squibb,                                                                                                                                
 Debiopharm and DCx Biotherapeutics, as follows: (i) 90% received from the Closing date until the 2nd anniversary thereof, (ii) 85% received from the 2nd anniversary of the Closing date until the 4th anniversary of the Closing date, 
 (iii) 80% received from the 4th anniversary of the Closing date until the 6th anniversary of the Closing date, and (iv) 75% received from the 6th anniversary of the Closing date until the 10th anniversary of the Closing date;       |

| iii) | 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of                                                                                                                         
 Repare’s product candidates and/or intellectual property related to Repare’s RP-1664 program, RP-3500 (Camonsertib) program, or any other license or disposition of Repare’s product candidates or research programs if such license or 
 disposition is entered into prior to the Closing date;                                                                                                                                                                                  |

| iv) | 100% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of    
 Repare’s Polq program, RP-3467, to any person with whom negotiations were initiated prior to the Closing date; and |

| v) | 50% of the net proceeds received by the 10th anniversary of the Closing date for any license or disposition of                                                                             
 Repare